z-logo
Premium
COMPARISON BETWEEN THYROID STIMULATING AND TSH‐BINDING INHIBITING IMMUNOGLOBULINS OF GRAVES' DISEASE
Author(s) -
MACCHIA E.,
FENZI G. F.,
MONZANI F.,
LIPPI F.,
VITTI P.,
GRASSO L.,
BARTALENA L.,
BASCHIERI L.,
PINCHERA A.
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb00652.x
Subject(s) - medicine , endocrinology , thyroid , graves' disease , thyrotropin receptor , antibody , in vivo , stimulation , immunology , biology , microbiology and biotechnology
SUMMARY In the sera of patients with Graves' disease abnormal thyroid ‘stimulating’ immunoglobulins have been demonstrated by in vivo and in vitro assay systems. Conflicting results have been reported when thyroid stimulating and thyrotrophin (TSH)‐binding inhibiting activities have been compared. The present study was performed in forty‐nine hyperthyroid Graves' patients to ascertain the relationships among TSH‐binding inhibiting immunoglobulins (TBII), measured by a radio‐receptor assay, thyroid stimulating antibody (TSAb), assayed by stimulation of adenylate cyclase‐cAMP system in human thyroid plasma membranes, and LATS, measured by McKenzie's mouse bioassay. TBII was detected in twenty‐one of forty‐nine (42·9%), TSAb in thirty‐five of forty‐nine (714%) and LATS in nineteen of forty‐nine (38·8%). TBII was also present in four of sixteen (25%) patients with other thyroid autoimmune disorders. When the results obtained with the different techniques were compared, correlation was found between LATS response and TSAb activity (r = 0·53, P < 0·001), while there was no correlation between TSAb and TBII activities and between LATS response and TBII activity. These data confirm that TSAb is a specific and sensitive marker of Graves' disease and suggest that TBII activity is not necessarily synonymous with thyroid stimulation, and could reflect a different phenomenon concomitantly produced.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here